SCHEMBL6563465

SCHEMBL6563465

CC(O)(CN)c1ccc(C(C)(O)CN)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.38
RECQL P46063 1/20 0.38
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
ALOX15 P16050 1/20 0.37
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
ESR2 Q92731 2/20 0.36
LMNA P02545 1/20 0.36
TYR P14679 1/20 0.36
ESR1 P03372 1/20 0.36
AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6561671 0.97 AOC3 (0.41) AOC3TAAR1KMT2AMEN1ALDH1A1
SCHEMBL12015994 0.91 TSHR (0.48) AOC3TAAR1KMT2AMEN1ALDH1A1
SCHEMBL22395252 0.89 KMT2A (0.58) KMT2AMEN1MAPTTDP1CYP3A4
SCHEMBL12352042 0.89 KMT2A (0.58) KMT2AMEN1MAPTTDP1CYP3A4
SCHEMBL3703681 0.89 TAAR1 (0.40) AOC3TAAR1KMT2AMEN1ALDH1A1
SCHEMBL7839746 0.89 HTR2C (0.38) AOC3TAAR1ALDH1A1ALOX15TSHR
SCHEMBL3703684 0.89 TAAR1 (0.40) AOC3TAAR1KMT2AMEN1ALDH1A1
SCHEMBL5967480 0.87 TAAR1 (0.60) TAAR1KMT2AALDH1A1MAPTALOX15
SCHEMBL9580777 0.87 TAAR1 (0.60) TAAR1KMT2AALDH1A1MAPTALOX15
SCHEMBL1269538 0.87 TAAR1 (0.60) TAAR1KMT2AALDH1A1MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296945-B1 SULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2004-08-04 EP disclosed
US-6703425-B2 ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY 2004-03-09 US disclosed
US-20030229102-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1296945-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
WO-2001096289-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229102-A1 Sulfonamide derivatives GRIN1, GRIN2A, SLC1A2 AOC3 3717/4885TAAR1 376/4885KMT2A 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.